What is the urgent management for a patient presenting with mild anemia, microcytosis, low RBC count, severe thrombocytopenia, hyperbilirubinemia, and markedly elevated LDH consistent with a hemolytic microangiopathy?

Urgent Management: Initiate Plasma Exchange Immediately for Suspected TTP

This patient requires URGENT empiric plasma exchange (PLEX) within 4-8 hours of presentation for presumed thrombotic thrombocytopenic purpura (TTP), even before ADAMTS13 results are available 1, 2, 3.

Clinical Presentation Analysis

Your patient's laboratory constellation is highly concerning for thrombotic microangiopathy (TMA), specifically TTP:

• Microangiopathic hemolytic anemia (MAHA): Anemia (Hgb 10.1) with microcytosis (MCV 68) and markedly elevated LDH (1025)
• Severe thrombocytopenia: Platelet count 55,000
• Indirect hyperbilirubinemia: Total bilirubin 5.8
• Normal RBC count (4.3 million) with low hemoglobin suggests hemolysis

The markedly elevated LDH (1025) combined with severe thrombocytopenia and hyperbilirubinemia creates a high probability of TTP, which is a medical emergency with mortality approaching 90% without treatment 2, 4.

Immediate Actions (Within 4-8 Hours)

1. Send ADAMTS13 Testing BEFORE Any Plasma Therapy

• Collect sodium citrate plasma sample immediately 3
• Send for ADAMTS13 activity, inhibitor, and anti-ADAMTS13 IgG
• Do NOT wait for results to start treatment 5, 4
• ADAMTS13 activity <10% confirms TTP diagnosis 1, 2, 6

2. Confirm MAHA on Peripheral Smear

• Look specifically for schistocytes (fragmented RBCs) 5, 6
• Even 1-3% schistocytes supports TMA diagnosis 4, 7
• Request urgent hematology review of smear

3. Calculate PLASMIC Score

Use this validated scoring system to assess pre-test probability of severe ADAMTS13 deficiency 2, 4:

• Platelet count <30,000: 1 point
• Hemolysis present: 1 point
• No active cancer: 1 point
• No transplant history: 1 point
• MCV <90: 1 point
• INR <1.5: 1 point
• Creatinine <2.0: 1 point

Score ≥5 indicates high probability of TTP requiring immediate treatment 4

4. Initiate Plasma Exchange Immediately

• Start PLEX within 4-8 hours of presentation 3
• Daily PLEX (1-1.5 plasma volumes) until platelet count normalizes 1
• Continue for minimum 2 days after platelet recovery
• This is the cornerstone of TTP treatment and reduces mortality from 90% to <5% 2

5. Add Corticosteroids

• High-dose methylprednisolone 1g IV daily × 3 days, then prednisone 1mg/kg 4
• Initiate concurrently with PLEX

6. Add Rituximab Early

• 375 mg/m² weekly × 4 doses 1
• Reduces relapse rates and accelerates remission
• Should be started during acute episode per 2020 ISTH guidelines 1

7. Consider Caplacizumab if Available

• Anti-VWF nanobody approved for iTTP 1, 2
• 10mg IV bolus before first PLEX, then 10mg SC daily
• Significantly reduces time to platelet normalization and organ damage
• Continue until 30 days after stopping PLEX 1

Critical Pitfalls to Avoid

DO NOT transfuse platelets unless life-threatening bleeding occurs—platelet transfusion may worsen microvascular thrombosis and organ damage 4.

DO NOT delay treatment waiting for ADAMTS13 results—turnaround time can be several days, and mortality increases dramatically with delayed treatment 2, 5, 4.

DO NOT assume this is simple iron deficiency anemia based on the microcytosis—the elevated LDH, thrombocytopenia, and hyperbilirubinemia override this consideration 5.

DO NOT rule out TTP based on absence of neurological symptoms or renal failure—the classic "pentad" is present in <10% of cases, and treatment should begin with just thrombocytopenia + MAHA 4, 8.

Additional Workup (Can Be Done Concurrently)

• Exclude other causes of TMA:

  • Coagulation studies (PT, aPTT, fibrinogen, D-dimer) to rule out DIC 5
  • Direct antiglobulin test (Coombs) to exclude autoimmune hemolysis 5
  • Haptoglobin (should be undetectable in hemolysis) 4
  • Reticulocyte count (should be elevated) 5, 4
  • Stool culture for Shiga toxin if diarrhea present 3
  • Blood cultures if febrile 7
  • Pregnancy test in women of childbearing age 3

• Assess for organ damage:

  • Troponin (cardiac involvement)
  • Creatinine (renal involvement)
  • Neurological examination (mental status, focal deficits)

Treatment Algorithm Based on ADAMTS13 Results

If ADAMTS13 Activity <10%:

• Continue PLEX + corticosteroids + rituximab + caplacizumab (if available) 1
• This confirms immune TTP (iTTP) if inhibitor/antibody positive
• Consider congenital TTP (cTTP) if antibody negative—will need genetic testing and may benefit from recombinant ADAMTS13 (Adzynma®) if available 1

If ADAMTS13 Activity >10%:

• Stop PLEX and reassess for other TMA causes 6, 3:
  • Complement-mediated TMA (atypical HUS)—consider eculizumab 6, 3
  • Shiga toxin-associated HUS—supportive care only 3
  • Drug-induced TMA—stop offending agent 8
  • Secondary TMA (malignancy, autoimmune, infection)—treat underlying cause 6, 7

Monitoring During Treatment

• Daily CBC with platelet count
• Daily LDH, bilirubin, haptoglobin
• Daily creatinine and troponin
• Continue PLEX until platelets >150,000 for 2 consecutive days AND LDH normalizing 1

The key to survival in TTP is recognizing the pattern of MAHA + thrombocytopenia and initiating PLEX immediately without waiting for confirmatory testing 2, 5, 4. With modern treatment including PLEX, corticosteroids, rituximab, and caplacizumab, survival exceeds 95% 2.